1. Introduction
The introduction of antibiotics into clinical medicine was one of the main prerequisites for the development of our present-day healthcare; previously deadly infections have suddenly become treatable, and the introduction of various medical interventions (invasive surgery, organ transplantation) and specialties (oncological care, neonatology) became possible [ 1 , 2 ]. The emergence of multidrug-resistant organisms (MDROs) is a global public health issue, which severely hinders clinicians in defining appropriate patient treatment options and treatment regimens [ 3 , 4 ]; the ramifications of the spread of drug-resistant pathogens are biggest in developing countries, significantly contributing to morbidity and mortality [ 5 , 6 ]. Based on their overall impact (mortality-wise and economically), the group of “ESKAPE” pathogens (this acronym was first proposed by Louis B. Rice in 2008), namely E: Enterococcus faecium , S: Staphylococcus aureus or recently Stenotrophomonas maltophilia , K : Klebsiella pneumoniae or recently C : Clostridioides difficile , A : Acinetobacter baumannii , P : Pseudomonas aeruginosa , E : Enterobacter spp., or recently Enterobacteriaceae ) present the most clinical challenges [ 7 ]. Some of these bacteria have also been included in the priority pathogens list, which was developed for pharmaceutical companies by the World Health Organization (WHO) to guide the development of new antimicrobial drugs [ 8 , 9 , 10 ]. Some of the main public health authorities (e.g., the WHO, the European Center for Disease Prevention and Control (ECDC), and the Centers for Disease Control and Prevention in the US (CDC)) have all published reports on the global impact of bacterial drug resistance and urged for global action to be taken [ 11 , 12 , 13 , 14 ]; among these publications; however, the O’Neill report (sequestered by the National Health Service (NHS) of the United Kingdom) is probably the most pessimistic, projecting 10 million deaths per year by 2050 and 100 billion USD worth of economic burden [ 15 ]. In addition to their inappropriate use in animal husbandry and human medicine, one of the main concerns regarding the therapy of MDROs is the unavailability of novel antibacterial agents [ 16 , 17 , 18 ]. The absolute costs of antimicrobial research and development (R&D), the financial risks associated with the organization of clinical trials, the inevitable and rapid emergence of drug-resistant mutants against these new drugs and the comparatively modest return on investment (ROI; which is a performance measure used to evaluate the efficiency of an investment) has resulted in pharmaceutical companies shifting their interests towards the therapy of chronic illnesses or leaving behind the antimicrobial research programs entirely [ 19 , 20 , 21 , 22 ]. This has resulted in a ‘dry’ antibiotic pipeline and no new broad-spectrum antibiotics since the introduction of the fluoroquinolones in the 1980s [ 23 , 24 ].
In lieu of new antibiotics, novel strategies have been proposed to combat bacterial pathogens more efficiently—among other things, combination therapy (the use of two or more existing antibiotics simultaneously) and the use of adjuvants (non-antibiotic drugs co-administered with an existing antibiotic) all present possible alternatives [ 25 , 26 ]. These adjuvants include agents already used in clinical practice, such as monoclonal antibodies (e.g., bezlotoxumab, neutralizing Clostridioides difficile toxin B) [ 27 ], β-lactamase inhibitors (e.g., clavulanic acid, avibactam) [ 28 ], and others, such as efflux pump inhibitors (EPIs; compounds capable of inhibiting bacterial transporter proteins that utilize proton motive force or the hydrolysis of ATP to remove various chemicals from bacterial cells) [ 29 , 30 ], modulators of bacterial membrane potential and membrane permeabilizers [ 26 ]. However, it’s worth noting that at present, none of the abovementioned EPIs or membrane permeabilizers can be used in clinical practice, due to the very high concentrations required for them to be effective, which usually corresponds to debilitating toxicity in vivo [ 29 , 30 ]. Another promising approach to treat bacterial infections is through the use of virulence inhibitors (or ‘pathoblockers’) [ 31 ]. The rationale behind the use of these compounds is that they do not affect the viability of bacterial cells in vivo; instead, they inhibit the synthesis or expression of bacterial virulence factors (e.g., exotoxins, secreted bacterial enzymes, biofilm) which are key in their pathogenesis, or modulate their genetic plasticity (i.e., competence) [ 32 , 33 , 34 , 35 ]. The potential advantage of these agents (compared to antibiotics) is that the selection pressure exerted by these drugs (and consequently, the chance of resistance development) is expected to be much lower; therefore, the rapid emergence of drug-resistant mutants is unlikely [ 36 , 37 ]. Some reports also suggest that anti-virulence drugs may have minor effects on the gut microbiome: they should be able to exert their activity without causing ‘collateral damage’ [ 38 , 39 ].
Bacterial quorum sensing (QS) is a distinct mechanism of cell-cell communication, during which bacteria can ‘sense’ the density of cells in the surrounding environment, resulting in the expression or suppression of specific genes [ 40 , 41 ]. Surrounding bacterial cell population density is established by the detection of diffusible signal molecules produced by surrounding cells, in addition, self-produced signals are also detected (activating positive feed-back circuits); if the concentration of these signal molecules (or autoinducers) reaches a critical concentration, transcription changes occur in various genes, which are important for benefits in fitness and reproductive success in their specific niche [ 40 , 42 , 43 ]. The phenomenon of QS was first described in 1968 by Kempner and Hanson in Vibrio fischeri (postulating that the culture media contained a luminescence inhibitor, which was removed if large numbers of bacteria were present [ 44 ]); however, the true mechanism of QS (namely, the initiation of phenotypic changes by the accumulation of autoinducers secreted by bacteria) was reported by Nealson et al. in 1970 [ 45 ], and Eberhard et al. in 1972 [ 46 ]. QS-signal molecules encompass a wide variety of structurally different molecules: in Gram-positive bacteria, peptide-based signal molecules (AIPs, autoinducing peptides) are most frequently detected, while in Gram-negatives, acyl-homoserine lactone-derivatives (AHLs) are the most prevalent; interestingly, some signal molecule-types (e.g., AI-2, a derivative of dihydroxy-2,3-pentanedione) may be detected by a wide range of bacteria, while others (e.g., Pseudomonas quinolone signal (PQS), diffusible signal factor (DSF)) are specific to one or a very few species [ 40 , 41 , 42 , 43 , 47 , 48 ]. The elimination or inhibition of QS-signal transmission is termed quorum quenching (QQ), which may be mediated by the use of signal-antagonists, inhibition of signal sensing, or synthesis, influencing bacteria on the level of gene expression and by the degradation of these signal molecules [ 42 , 47 ]. Synthetic molecules (i.e., quorum quenching based on inhibition) may inhibit signal transduction mechanisms relevant in virulence factor-expression of relevant pathogens, therefore disarming them in vivo [ 41 , 49 , 50 ]. From the viewpoint of the development of virulence inhibitors, quorum quenching is a promising route, because various important bacterial features in physiology and virulence (e.g., production of toxic shock syndrome toxin in Staphylococcus aureus , elastase in P. aeruginosa , protease in V. cholerae ; activity of bacterial secretion systems (e.g., Salmonella species) and efflux pumps (e.g., P. aeruginosa, Escherichia coli ), biofilm-production (e.g., P. aeruginosa , Acinetobacter baumannii , Stenotrophomonas maltophilia ); induction of bacterial competence (e.g., Streptococcus pneumoniae ), motility (e.g., P. aeruginosa ), adhesion (e.g., E. coli, Klebsiella pneumoniae ) and pigment-production (e.g., Chromobacterium violaceum , Serratia marcescens , P. aeruginosa )) are mediated by QS-dependent gene expression [ 31 , 40 , 51 , 52 ]. Due to its promise for future applications in human medicine, research on quorum sensing and quorum quenching has garnered significant attention in the last 15–20 years (see Supplementary Figure S1 for bibliometric assessment).
Drug repurposing (also called drug re-profiling or repositioning) is a drug development strategy, during which new pharmacological uses are identified for already approved drugs, outside of their original designated medical indications [ 39 , 53 ]. This strategy offers various advantages: the chemical and technological aspect of these molecules are already established, the toxicity, safety and pharmacokinetic profile of the drug is known; therefore, early stages of the drug development process (preclinical in vitro and animal models, Phase I–II clinical trials) may be avoided, leading to substantial savings for the pharmaceutical companies [ 39 , 53 , 54 ]. Although the costs of organizing Phase III–IV trials are still considerable, if the new indication for the drugs is appropriate, drug companies may still expect sizeable ROIs. Previously, drug repurposing was mainly based on serendipitous discoveries or retrospective analyses of clinical data; nowadays, there are initiatives to systematically screen the existing drug pool for off-target effects, which may be suitable for the development of additional clinical indications [ 39 , 53 , 54 ]. Examples of the success of drug repurposing include the use of thalidomide (morning sickness → multiple myeloma, erythema nodosum leprosum), minoxidil (hypertension → alopecia), ketoconazole (antifungal drug → Cushing syndrome), aspirin (analgesia → colorectal cancer), and sildenafil (angina pectoris → erectile dysfunction → pulmonary hypertension) in new clinical indications [ 53 ].
Drug repurposing is also a promising strategy in the therapy of bacterial infections: many pharmaceuticals have secondary mechanisms of action (some of which are not fully characterized), which allows them to be efficacious against various pathogens, either as directly acting antibacterial agents or as virulence inhibitors [ 55 ]. For this reason, there is interest in the screening of the existing pool of pharmaceutical agents as anti-virulence drugs; however, there are significant gaps in knowledge in this field [ 56 , 57 , 58 ]. The aim of our present study was to assess the suitability of a selection of non-antibiotic pharmacological agents as QS-inhibitors, with various in vitro bacterial model systems, using disk-diffusion based QS-inhibitory (DDBQSI) assays.
2. Results and Discussion
2.1. Antibacterial Activity
Among the tested pharmaceutical agents, fourteen (namely celecoxib, mebendazole, ivermectin, verapamil, promethazine, chlorpromazine, thioridazine, methotrexate, doxorubicin, bleomycin, atorvastatin, simvastatin, clotrimazole , and fluconazole ) showed antibacterial activity in the tested concentration range (0.25–250 µg/mL), while the other agents in the study had no relevant antibacterial properties on the bacterial strains used in this study (minimal inhibitory concentrations [MIC] > 250 µg/mL; Table 1 ). The most potent antibacterial activity was noted for chlorpromazine, thioridazine and mebendazole (consistently for all tested strains), in addition, MICs were recorded in the moderate range regarding the tested statins (for Enterobacter cloacae ), promethazine (for Chromobacterium violaceum wt85 and CV026), celecoxib (for S. aureus ) and ivermectin (for S. aureus ). The antibacterial activity of the tested antipsychotic drugs became more potent with the progression of the different generation drugs (promethazine is a non-selective, first-generation phenothiazine, while thioridazine is a newer drug of the same group) [ 59 ]; these compounds have been extensively characterized as efflux pump inhibitors, while the antibacterial activity of these drugs is partly attributed to their intercalation into DNA [ 60 ]. Anthracyclines (including doxorubicin) and bleomycin are frequently termed ‘ anticancer antibiotics ’; therefore, it is not surprising that the antibacterial properties of these drugs were observed [ 61 , 62 ]. Similarly to the phenothiazines, their antibacterial activity is also attributed to bacterial DNA-intercalation, while it is debated whether their potency to produce semiquinone-based oxidative free radicals in the presence of Fe 2+ -ions (which is an important factor of their anticancer activity in vivo) is important in this regard [ 61 , 62 , 63 , 64 ]. Atorvastatin was effective in a 1–2-fold lower dose than simvastatin; although the exact mechanism of action is uncertain, some reports suggest that they interfere with the mevalonate pathway (similarly to eukaryotic cells) and the synthesis of the major lipid constituents of cell membrane microdomains [ 51 , 65 , 66 ]. In line with previous reports, ivermectin, celecoxib, and the azole-type antifungal agents were only effective against Gram-positive bacteria (in our case S. aureus ATCC 25923) [ 67 , 68 , 69 ]. The MIC values recorded in this experiment were used to set the starting doses of these drugs in the QS-inhibition assays to distinguish between their quorum quenching and antibacterial properties [ 70 ]. The MICs of acridine orange have been previously reported at 125 µg/mL on the QS-sensor strains ( C. violaceum wt85, CV026, and Serratia marcescens AS-1) and >250 µg/mL for the other tested bacterial strains [ 71 ]. The results on the control strains ( S. aureus and E. coli ATCC strains) were adequate and in line with findings in the literature [ 59 , 60 , 65 , 67 , 68 , 69 ].
2.2. Screening and Semi-Quantitative Assessment of QS-Inhibitory Activity
Among the forty-five tested pharmaceutical compounds, eight drugs (namely 5- fluorouracil, metamizole-sodium, cisplatin, methotrexate, bleomycin, promethazine, chlorpromazine, and thioridazine ) showed relevant QS-inhibitory activity in the cross-inoculation experiments with C. violaceum wt85 and S . marcescens AS-1; therefore, these compounds were included in the parallel inoculation assay (with S . marcescens AS-1, and the C. violaceum CV026 + AHL-producer-pair combinations) to quantify the QS-inhibition of these agents, while the other pharmaceutical agents were not tested further; the result of these experiments is presented in Figure 1 , Figure 2 , Figure 3 and Figure 4 and in the Supplementary Table S1 (expressed as QS-inhibition zone diameters with SD values for each respective model systems). DMSO, 70% ethanol, 85% glycerol, and acetone were also tested as solvent controls in the cross-inoculation experiments, where they presented with no QS-inhibitory effects.
Compared to acridine orange (AO), the QS-inhibitory effects of metamizole-sodium, cisplatin and methotrexate were less potent, with 2–10 times smaller QS-inhibition zones), while the phenothiazine-derivatives, bleomycin, and 5-fluorouracil exhibited concentration-dependent QS-inhibitory activity, which was more potent than AO in almost all cases when tested at the same or even at lower doses (QS-inhibition zones 1.5–3-times larger than in the case of AO, or the activity in doses where the positive control showed no QS-inhibition; Figure 1 , Figure 2 , Figure 3 and Figure 4 ). When it comes to the phenothiazines, the potency of QS-inhibition increased with the progression of the different generation drugs (promethazine → thioridazine), similarly to their antibacterial activity. Interestingly, some agents, which presented with antibacterial activities ( celecoxib, mebendazole, ivermectin, verapamil, doxorubicin, atorvastatin, simvastatin, clotrimazole, fluconazole ) did not show QS-inhibitory properties, while others (metamizole-sodium, cisplatin) had no antibacterial activity while being QS-inhibitors ( Figure 1 , Figure 2 , Figure 3 and Figure 4 ). Overall, the most potent QS-inhibitor (among the tested pharmaceutical compounds) was 5-fluorouracil, and the S . marcescens model system presented as the most sensitive for the QS-inhibitory activity of the tested compounds (i.e., inhibition of prodigiosin pigment production), while among the C . violaceum CV026 and AHL-producer pair system, the following order may be set up in regards to sensitivity, based on our results: 1. C . violaceum CV026 and Sphingomonas paucimobilis Ezf 10–17 (most sensitive), 2. C . violaceum CV026 and E . cloacae 31298, 3. C . violaceum CV026 and Novosphingobium spp. Rr 2–17 (least sensitive) ( Figure 1 , Figure 2 , Figure 3 and Figure 4 .). The mechanism of action of the active pharmaceutical drugs has not been described: as signal molecule-degradation (i.e., quorum quenching by degradation) mainly occurs with compounds with enzymatic activity (e.g., the human paraoxonase enzyme, which is essentially a lactonase), findings of other studies in the literature suggest that these drugs exert their QS-inhibitory properties through inhibition of signal detection or through modifying gene expression in these bacteria [ 42 , 47 ].
There are several studies reporting on the QS-inhibitory activity of antibiotics (e.g., azithromycin, gentamicin, tobramycin, and fluoroquinolones) or the successful use of QS-inhibitory compounds together with conventional antibiotics in vitro and in animal models [ 72 , 73 , 74 ]. Non-antibiotic pharmaceutical drugs and compounds derived from various natural sources and foos have attracted reasonable attention as novel antibacterial agents or adjuvant compounds (efflux pump inhibitors, membrane permeabilizers, QS-inhibitors) because their physicochemical and in vivo biological properties have been previously described [ 25 , 26 , 30 , 39 , 53 ], a summary of relevant compounds and corresponding literature is presented in Table 2 . The characterization of the antibacterial and QS-inhibitory activity of the abovementioned compounds was performed through the utilization of different in vitro model systems (e.g., Aeromonas spp., Agrobacterium tumefaciens , Bacillus subtilis , Burkholderia cepacia , Chromobacterium spp., E. coli , Serratia spp., P. aeruginosa PAO1, V. harveyi , S. aureus , S. maltophilia ) and molecular testing methods (e.g., detection of differences in gene expression levels with PCR) [ 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 ].
Although it is difficult to assess the detected activity of these drug molecules in relation to previous publications, because most of these reports used different model systems (e.g., inhibition of swarming motility or elastase-, protease-production of P. aeruginosa PAO1, to the detection of gene-expression changes in P. aeruginosa , S. maltophilia or S. aureus , or experimental animal-based systems, where a lung, soft tissue, or other infection models are used), it can be observed that most of the mentioned compounds exerted QS-inhibitory properties in the same dose range or in doses 1–2-fold lower than in our studies, these differences are presumably due to the different sensitivities of these model systems utilized, while in animal systems, the tissue distribution of the compounds should also be taken into consideration [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 ].
Some reports also suggested that various vitamins have potent adjuvant properties, enhancing the bactericidal activity of antibiotics ( Table 2 ), and they also exert their own antibacterial activities in very high concentrations [ 103 , 104 , 105 , 106 , 107 ]. Nevertheless, the tested vitamins and antioxidants (Vitamin B 1 , Vitamin B 6 , Vitamin B 12 , Vitamin C, Vitamin D, Vitamin E, Coenzyme Q 10 ) did not show any antibacterial or QS-inhibitory activity during our experiments.
Highlights of the study : during our experiments, the antibacterial and QS-inhibitory capacities of 45 currently used pharmacological agents (sourced from diverse clinical indications and molecular characteristics) have been tested in a semi-quantitative in vitro model, for which such data were not available whatsoever, or data were generated on different model systems. Fourteen of the tested drugs showed varying degrees of antibacterial activity on the tested bacterial strains, while five drugs (promethazine, chlorpromazine, thioridazine, 5-fluorouracil, and bleomycin) showed dose-dependent QS-inhibitory activity, which was more potent than acridine orange. Based on the results of this experiment, the characterization of active pharmaceutical compounds on different QS-based model systems is highly recommended, in addition, the continuous screening of the existing drug pool may result in the establishment of a library of clinically relevant drugs with virulence-modulating properties. The in vitro antibacterial properties of the tested drugs highlight the tendency of some non-antibiotic pharmacological agents to affect bacterial viability, which is important in the context of the human gut microbiome: in addition to antibiotics, these drugs may also have detrimental effects on the species composition of gut bacteria (leading to disease), therefore this study provides novel insights in this aspect as well [ 118 ].
Limitations of the study: during our experiments, the QS-inhibitory activity of the compounds was only tested against strains, where cell-cell communication is based on AHL-signal molecules and their activity was not characterized on the genetic level with molecular methods. To further establish the QS-inhibitory and anti-virulence properties of the tested drugs, further experiments with additional Gram-positive (e.g., including AI-2-producing Bacillus species, toxin-producing S. aureus ), and Gram-negative (e.g., elastase-production and motility-assays with P. aeruginosa (PQS-mediated), S. maltophilia (DSF-mediated) bacterial model systems should be considered.
3. Materials and Methods
3.1. Chemicals
3.1.1. Pharmaceutical Compounds
Forty-five pharmacological agents, encompassing a wide variety of different chemical structures and mechanisms of action were tested during our experiments: 1. non-steroidal anti-inflammatory drugs (NSAIDs): acetylsalicylic acid (Sigma-Aldrich; Budapest, Hungary; will be listed as SA in the subsequent text), indomethacin (Sanofi; Paris, France; will be listed as SP in the subsequent text), metamizole-sodium (SF), diclofenac (SA), celecoxib (Pfizer Hungary Ltd.; Budapest, Hungary), acetaminophen (SA), 2. antiviral and antifungal drugs: acyclovir (Teva Pharmaceuticals; Petah Tikva, Israel; will be listed as TPh in the subsequent text), cidofovir (SA), amantadine (SA), clotrimazole (TPh), fluconazole (SA), terbinafine (GlaxoSmithKline Hungary Ltd., Budapest, Hungary), 3. anthelmintic drugs: mebendazole (Richter Pharmaceuticals; Budapest, Hungary; will be listed as RPh in the subsequent text), ivermectin (SA), 4. anti-allergy medications (H 1 -receptor antagonists and decongestants): cetirizine (SA), azelastine (SA), xylomethazoline (SA), 5. drugs targeting the cardiovascular system: metoprolol succinate (SA), enalapril maleate (SA), valsartan (SA), verapamil (TPh), simvastatin (SA), atorvastatin (SA), 6. mucolytics and antitussives: ambroxol (TPh), acetyl-cysteine (TPh), guaifenesin (SA), 7. neuroleptic drugs: promethazine (SA), chlorpromazine (SA), thioridazine (SA), 8. antimetabolite anticancer agents: methotrexate (Ebewe Pharma, Unterach am Attersee, Austria), 5-fluorouracil (TPh), gemcitabine (TPh), 9. alkylating anticancer agents: cyclophosphamide (Baxter; Deerfield, IL, United States), cisplatin (TPh), 10. anticancer drugs affecting the microtubule system or topoisomerase-enzymes: vincristine (TPh), paclitaxel (TPh), doxorubicin (TPh), topotecan (SA), bleomycin (TPh), 11. vitamins and antioxidants: Vitamin B 1 (EGIS Pharmaceuticals; Budapest, Hungary; will be listed as EGIS in the subsequent text), Vitamin B 6 (EGIS), Vitamin B 12 (RPh), Vitamin C (SA), Vitamin D (EGIS), Vitamin E (SA), Coenzyme Q 10 (SA). Pharmaceutical compounds were dissolved in phosphate-buffered saline, with the exception of simvastatin and atorvastatin, which were dissolved in DMSO, in addition to Vitamin D and Coenzyme Q 10 , which were dissolved in acetone and 70% ethanol, respectively.
3.1.2. Media Constituents and Other Reagents
Bacteriological agar (Bio-Rad Hungary Ltd.; Budapest, Hungary), tryptone (Thermo Fischer Scientific; Waltham, MA, USA; will be listed as TFS in the subsequent text), yeast extract (TFS), d -glucose (SA), kanamycin (SA), NaCl (SA), K 2 HPO 4 (SA), KH 2 PO 4 (SA), MgSO 4 × 7H 2 O (SA), CaCl 2 × 2H 2 O (SA), FeSO 4 × 7H 2 O (SA), Na 2 EDTA (SA), MnSO 4 × 7H 2 O (SA), ZnSO 4 × 7H 2 O (SA), Na 2 MoO 4 × 2H 2 O (SA), CoCl 2 × 6H 2 O (SA), dimethyl-sulfoxide (DMSO; SA), acetone (SA), acridine orange (AO; SA), 70% ethanol (SA), 85% glycerol (SA), and phosphate-buffered saline (PBS; SA). During the preparation of the modified Luria-Bertani agar (LB*-A, Bio-Rad Hungary Ltd.; Budapest, Hungary), the following stock solutions were used: 5% Fe-EDTA stock solution, 3% CaCl 2 stock solution, and a microelement stock solution (containing 1.0 g MnSO 4 × 7H 2 O, 0.5 g ZnSO 4 × 7H 2 O, 25 mg Na 2 MoO 4 × 2H 2 O and 2.5 mg CoCl 2 × 6H 2 O per 100 mL). The stock solutions were aliquoted in 50 mL centrifuge tubes and kept at –20 °C till use.
3.2. Bacterial Strains
The following bacterial strains were used during our QS-inhibition experiments: Chromobacterium violaceum wt85 (wild-type strain, characterized by the AHL signal molecule-mediated production of the purple violacein pigment, capable of the production of endogenous QS-signal molecule (N-hexanoyl-L-HSL)), C. violaceum CV026 (Tn5 transposase-mutant, AHL-signal molecule indicator strain: incapable of endogenous QS-signal molecule-production, but produces purple violacein pigment in the presence of external AHL stimuli) [ 70 , 71 ], Enterobacter cloacae clinical isolate no. 31298 (isolated from a wound sample, AHL-producing-strain (used with C. violaceum CV026)) [ 70 , 71 ], Sphingomonas paucimobilis Ezf 10– 17 (isolated from a tumor of the “Ezertűfű” variety of the common grapevine ( Vitis vinifera ), AHL-producing-strain (used with C. violaceum CV026)), Novosphingobium spp. Rr 2–17 (isolated from a tumor of the “Rajnai rizling” variety of the common grapevine ( Vitis vinifera ), AHL-producing-strain (used with C. violaceum CV026)) [ 119 ], Serratia marcescens AS-1 (characterized by the production AHL signal molecule-mediated production of the orange-red pigment prodigiosin (2-methyl-3-pentyl-6-methoxyprodigiosin), capable of endogenous QS-signal molecule-production (N-hexanoyl-L-HSL)) [ 120 ]. In addition, Staphylococcus aureus ATCC 25923 and Escherhichia coli ATCC 25922 were used as control strains.
The QS-sensory and indicator of bacterial strains for our experiments were kindly provided by Dr. Ernő Szegedi (Institute of Viticulture and Enology, National Agricultural Research Center; Badacsonytomaj, Hungary). For shorter time periods (<1 month), the bacterial strains were maintained on Luria-Bertani (LB) agar, while for longer periods, the strains were kept in a –80 °C freezer, in a 1:4 mixture of 85% glycerol and liquid Luria-Bertani (LB-B) medium. For the maintenance purposes of C. violaceum CV026, the media were also supplemented with kanamycin.
3.3. Culture Media
The following culture media were used during our experiments: cation-adjusted Mueller–Hinton broth (CMH-B; Bio-Rad Hungary Ltd., Budapest, Hungary), Luria–Bertani broth (LB-B), and Luria–Bertani agar (LB-A) (Bio-Rad Hungary Ltd., Budapest, Hungary) which were purchased, while the modified Luria–Bertani agar (LB*-A) (which was used during the QS-inhibition assays; containing 8.0 g tryptone, 5.0 g yeast extract, 5.0 g NaCl, 2.0 g d -glucose, 1.0 g K 2 HPO 4 , 0.2 g MgSO 4 × 7H 2 O, 10 mL 3% CaCl 2 stock solution, 5 mL Fe-EDTA stock solution, 1 mL microelement stock solution, and 12.0 g of bacteriological agar per 1 L of media; pH was adjusted to 7.0–7.2) was prepared in-house [ 71 ].
3.4. Antibacterial Activity
As a part of our study, the antibacterial activity of non-antibiotic pharmaceutical compounds on QS-sensory and signal molecule-producing bacterial strains was determined. The purpose of the assay was to screen for possible antibacterial activity of the tested compounds so that later on, their potential QS-inhibitory activities and their bacterial population density-reducing properties (due to their bacteriostatic or bactericidal effects) in the subsequent QS-inhibition assays could be distinguished. The minimum inhibitory concentrations (MICs) of the tested compounds were determined using the standard broth microdilution (BMD) method, based on the recommendations of the Clinical and Laboratory Standards Institute (CLSI; M07-A10). The experiments were performed in 96-well polystyrene microtiter plates, using cation-adjusted Mueller–Hinton broth (CMH-B), the tested concentrations of the compounds were ranging between 0.25–250 µg/mL. During the experiments with S. aureus ATCC 25922, CMH-B was supplemented by 2% NaCl. The plates were incubated at 37 °C in an air thermostat; the MIC values of the tested compounds were recorded after 16–18 h of incubation; the interpretation of the results was performed using a photometer. S. aureus ATCC 25923 and E. coli ATCC 25922 were tested as control strains. All experiments were performed in triplicate.
3.5. Screening for and Semi-Quantitative of QS-Inhibitory Activity Using Disk Diffusion Method
The screening and quantification of the QS-inhibitory activity of the tested compounds were performed using the disk diffusion method, the detailed description and optimization of these methods were previously described [ 71 , 101 , 121 ]. Screening for the QS-inhibitory activity of the tested compounds was performed using the cross-inoculation method (see Supplementary Material Figure S2 ). Briefly, overnight bacterial cultures of C. violaceum wt85 and S. marcescens AS-1 (at OD 580 ~ 0.5) grown in LB-B broth were inoculated directly onto LB*-A agar surface in a crossing pattern (see Supplementary Figure S2 ). Filter paper disks (7.0 mm in diameter, Whatman 3MM) were impregnated with 10 µL of the solutions of the tested compounds (at 1.56–50 µg/mL, depending on the MICs of the respective drugs, see Section 3.4 ), which were placed at the center of the crossing pattern right after the plates were inoculated. Before the evaluation, the plates were incubated for 48 h at room temperature.
If detectable QS-inhibition (discolored, but intact bacterial colonies around the treated paper disk) was observed for a tested pharmaceutical compound, their QS-inhibitory activity was quantified using the parallel inoculation method ( Figure 5 and Figure 6 ). Pair combinations of the used sensor strain C. violaceum CV026 and the AHL-signal-producing strains (either E. cloacae 31298, S. paucimobilis Ezf 10–17 or Novosphingobium spp. Rr 2–17) were inoculated directly onto the LB*-A agar surface in parallel, at a 5 mm distance from each other, while S. marcescens AS-1 was inoculated as a single line (capable of producing prodigiosin from endogenous AHL-signals) [ 71 , 101 , 121 ]. Filter paper disks (impregnated with 10 µL of the solutions of the different solutions of the tested compounds) were placed on the center of the inoculated line(s). To quantify the QS inhibitory effect of the drugs, the diameter of the QS-inhibition zones (i.e., the size of discolored bacterial colonies with no growth inhibition) around the disks was measured using a caliper. The results of the studies are derived from the average of at least five independent experiments.
4. Conclusions
Infections caused by MDROs are associated with excess morbidity (sequelae, decrease in the quality of life) and mortality worldwide. Since the 21st century, antibacterial drug development has been slow to keep up with the rapid developments in the levels of bacterial resistance. Anti-virulence may offer a new wave of potential antibacterial therapeutics in the future, which drugs that will presumably have longer periods of clinical usefulness, compared to antibiotics. QS-based modulation of bacterial virulence is a straightforward and attractive drug development avenue. Nowadays, several thousands of drug compounds are marketed for human therapeutic purposes: these pharmaceuticals may be considered as a potentially untapped source of QS-inhibitory agents with different chemical structures and mechanisms of action, as the pharmacokinetic parameters and tolerability of these compounds have already been demonstrated in vivo. In our experiments, we have demonstrated the antibacterial and QS-inhibitory effects of various pharmaceutical molecules, contributing to the ‘ chemical information space ’ of QS-inhibition. Based on our promising results, further experiments involving the screening of additional pharmaceutical compounds and the utilization of more model systems are warranted.
Acknowledgments
The authors would like to thank Anikó Váradi Vigyikán for texcellent laboratory assistance. The authors express their gratitude to Ernő Szegedi for providing the QS-signal indicator and single-producing strains for our study. This study was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP 4.2.4. A/2-11-1-2012-0001 ‘National Excellence Program’. M.G. was supported by the National Youth Excellence Scholarship [Grant Number NTP-NTFÖ-18-C-0225] and the ESCMID Mentorship and Observership Programme. Part of this study was presented at the 18th International Congress of the Hungarian Society for Microbiology (MMT; Budapest, Hungary).
Supplementary Materials
The following are available online at https://www.mdpi.com/2079-6382/8/4/270/s1 . Figure S1: Results of a literature search in the PubMed/MEDLINE database on the keywords “quorum sensing” and “quorum quenching”, Figure S2: Screening for QS-inhibitory activity with the cross-inoculation disk diffusion method, using Chromobacterium violaceum wt85 (left) and) and Serratia marcescens AS-1 (right), Table S1: Quorum sensing-inhibitory activity of selected pharmacological agents.
Click here for additional data file.
Author Contributions
M.G. conceived and designed the study. G.S. provided the resources and the laboratory equipment for the experiments. M.G. and G.S. performed the biological studies, interpreted the biological results, wrote, and revised the full paper.
Funding
The study received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Gaynes R. The Discovery of Penicillin—New Insights after More Than 75 Years of Clinical Use Emerg. Infect. Dis. 2017 23 849 853 10.3201/eid2305.161556
2. Shallcross L.J. Howard S.J. Fowler T. Davies S.C. Tackling the threat of antimicrobial resistance: From policy to sustainable action Philos Trans. R. Soc. Lond. B Biol. Sci. 2015 370 20140082 10.1098/rstb.2014.0082 25918440 PMC4424432
3. Aslam B. Wang W. Arshad M.I. Khurshid M. Muzammil S. Rasool M.H. Nisar M.A. Alvi R.F. Aslam M.A. Qamar M.U. Antibiotic resistance: A rundown of a global crisis Infect. Drug Resist. 2018 11 1645 1658 10.2147/IDR.S173867 30349322 PMC6188119
4. Nathan C. Cars O. Antibiotic Resistance—Problems, Progress, and Prospects NEJM 2014 371 1761 1763 10.1056/NEJMp1408040 25271470
5. Cassini A. Högberg L.D. Plachouras D. Quattrocchi A. Hoxha A. Simonsen G.S. Colomb-Cotinat M. Kretzschmar M.E. Devleesschauwer B. Cecchini M. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis Lancet Infect. Dis. 2019 19 56 66 10.1016/S1473-3099(18)30605-4 30409683 PMC6300481
6. Gajdács M. Extra deaths due to pandrug resistant bacteria: A survey of the literature Egészségfejlesztés 2019 60 31 36
7. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE J. Infect. Dis. 2008 197 1079 1081 10.1086/533452 18419525
8. Boucher H.W. Talbot G.H. Bradley J.S. Edwards J.E. Gilbert D. Rice L.B. Scheld M. Spellberg B. Bartlett J. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009 48 1 12 10.1086/595011 19035777
9. Santajit S. Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens Biomed. Res. Int. 2016 2016 2475067 10.1155/2016/2475067 27274985 PMC4871955
10. Nasim J. Witek K. Kincses A. Abdin A.Y. Żesławska E. Marć M.A. Gajdács M. Spengler G. Nitek W. Latacz G. Pronounced activity of aromatic selenocyanates against multidrug resistant ESKAPE bacteria New J. Chem. 2019 43 6021 6031 10.1039/C9NJ00563C
11. World Health Organization Antimicrobial Resistance: Global Report on Surveillance Available online: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1 (accessed on 27 October 2019)
12. CDC Antibiotic/Antimicrobial Resistance (AR/AMR) Available online: https://www.cdc.gov/drugresistance/biggest_threats.html (accessed on 27 October 2019)
13. The Bacterial Challenge: Time to React. ECDC/EMEA Joint Technical Report (2009) Available online: http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf (accessed on 27 October 2019)
14. Laxminarayan R. Duse A. Wattal C. Zaidi A.K.M. Wertheim H.F.L. Sumpradit N. Vlieghe E. Hara G.L. Gould I.M. Goossens H. Antibiotic resistance-the need for global solutions Lancet Infect. Dis. 2013 13 1057 1098 10.1016/S1473-3099(13)70318-9 24252483
15. O’Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations Available online: https: //amr-review.org/sites/default/files/AMRReviewPaper-Tacklingacrisisforthehealthandwealthofnations_1.pdf (accessed on 27 October 2019)
16. Gajdács M. Szabó A. Physicians’ opinions towards antibiotic use and resistance in the southeastern region of Hungary Orv. Hetil. 2019 accepted 10.1556/650.2019.31598 32088975
17. Dyar O.J. Huttner B. Schouten J. Pulcini C. What is antimicrobial stewardship? Clin. Microbiol. Infect. 2017 23 793 798 10.1016/j.cmi.2017.08.026 28882725
18. Cheng G. Hao H. Xie S. Wang X. Dai M. Huang L. Yuan Z. Antibiotic alternatives: The substitution of antibiotics in animal husbandry? Front. Microbiol. 2014 5 217 10.3389/fmicb.2014.00217 24860564 PMC4026712
19. Projan S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 2003 6 427 430 10.1016/j.mib.2003.08.003 14572532
20. Boggs A.F. Miller G.H. Antibacterial drug discovery: Is small pharma the solution? Clin. Microbiol. Infect. 2004 10 32 36 10.1111/j.1465-0691.2004.1008.x 15522038
21. Hughes D. Karlén A. Discovery and preclinical development of new antibiotics Ups. J. Med. Sci. 2014 119 162 169 10.3109/03009734.2014.896437 24646082 PMC4034554
22. Gajdács M. The Concept of an Ideal Antibiotic: Implications for Drug Design Molecules 2019 24 892 10.3390/molecules24050892 PMC6429336 30832456
23. Lewis K. Platforms for antibiotic discovery Nat. Rev. Drug Discov. 2013 12 371 387 10.1038/nrd3975 23629505
24. Gajdács M. Albericio F. Antibiotic Resistance: From the Bench to Patients Antibiotics 2019 8 129 10.3390/antibiotics8030129 PMC6783868 31461842
25. Wright G.D. Antibiotic Adjuvants: Rescuing Antibiotics from Resistance Trends Microbiol. 2016 24 862 871 10.1016/j.tim.2016.06.009 27430191
26. Kealey C. Creaven C.A. Murphy C.D. Brady C.B. New approaches to antibiotic discovery Biotechnol. Lett. 2017 39 805 817 10.1007/s10529-017-2311-8 28275884
27. Alonso C.D. Mahoney M.V. Bezlotoxumab for the prevention of Clostridium difficile infection: A review of current evidence and safety profile Infect. Drug Resist. 2018 12 1 9 10.2147/IDR.S159957 30588042 PMC6301304
28. Drawz S.M. Bonomo R.A. Three Decades of β-Lactamase Inhibitors Clin. Microbiol. Rev. 2010 23 160 201 10.1128/CMR.00037-09 20065329 PMC2806661
29. Tegos G.P. Haynes M. Strouse J.J. Khan M.M. Bologa C.G. Oprea T.I. Sklar L.A. Microbial Efflux Pump Inhibition: Tactics and Strategies Curr. Pharm. Des. 2011 17 1291 1302 10.2174/138161211795703726 21470111 PMC3717411
30. Spengler G. Kincses A. Gajdacs M. Amaral L. New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria Molecules 2017 22 468 10.3390/molecules22030468 PMC6155429 28294992
31. Calvert M.B. Jumde V.R. Titz A. Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections Beilstein. J. Org. Chem. 2018 14 2607 2617 10.3762/bjoc.14.239 30410623 PMC6204809
32. Cegelski L. Marshall G.R. Eldridge G.R. Hultgren S.J. The biology and future prospects of antivirulence therapies Nat. Rev. Microbiol. 2008 6 17 27 10.1038/nrmicro1818 18079741 PMC2211378
33. Brannon J.R. Hadjifrangiskou M. The arsenal of pathogens and antivirulence therapeutic strategies for disarming them Drug Des. Devel. 2016 10 1795 1806 10.2147/DDDT.S98939 PMC4890686 27313446
34. Dickey S.W. Cheung G.Y.C. Otto M. Different drugs for bad bugs: Antivirulence strategies in the age of antibiotic resistance Nat. Rev. Drug Discov. 2017 16 457 471 10.1038/nrd.2017.23 28337021 PMC11849574
35. Lyons B.J.E. Strynadka N.C.J. On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome Med. Chem. Commun. 2019 10 1273 1289 10.1039/C9MD00146H 31534650 PMC6748289
36. Totsika M. Disarming pathogens: Benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability Future Med. Chem. 2017 9 267 269 10.4155/fmc-2016-0227 28207349
37. Gutiérrez-Barranquero J.A. Reen F.J. McCarthy R.R. O’Gara F. Deciphering the role of coumarin as a novel quorum sensing inhibitor suppressing virulence phenotypes in bacterial pathogens Appl. Microbiol. Biotechnol. 2015 99 3303 3316 10.1007/s00253-015-6436-1 25672848
38. Stewardson A. Gaia N. Francois P. Malhotra-Kumar S. Delemont C. Martinez de Tejada B. Schrenzel J. Harbarth S. Lazarevic V. Vervoort J. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut microbiota Clin. Microbiol. Infect. 2015 21 344.e1 344.e11 10.1016/j.cmi.2014.11.016 25658522
39. Xue H. Li J. Xie H. Wang Y. Review of Drug Repositioning Approaches and Resources Int. J. Biol. Sci. 2018 14 1232 1244 10.7150/ijbs.24612 30123072 PMC6097480
40. Miller M.B. Bassler B.L. Quorum Sensing in Bacteria Annu. Rev. Microbiol. 2001 55 165 199 10.1146/annurev.micro.55.1.165 11544353
41. Jiang Q. Chen J. Yang C. Yin Y. Yao K. Quorum Sensing: A Prospective Therapeutic Target for Bacterial Diseases Available online: https://www.hindawi.com/journals/bmri/2019/2015978/ (accessed on 27 October 2019) 10.1155/2019/2015978 PMC6475571 31080810
42. Whiteley M. Diggle S.P. Greenberg E.P. Bacterial quorum sensing: The progress and promise of an emerging research area Nature 2017 551 313 320 10.1038/nature24624 29144467 PMC5870893
43. Abisado R.G. Benomar S. Klaus J.R. Dandekar A.A. Chandler J.R. Bacterial Quorum Sensing and Microbial Community Interactions mBio 2018 9 e02331 e02417 10.1128/mBio.02331-17 29789364 PMC5964356
44. Kempner E.S. Hanson F.E. Aspects of light production by Photobacterium fischeri J. Bacteriol. 1968 95 975 979 5643069 10.1128/jb.95.3.975-979.1968 PMC252118
45. Nealson K.H. Platt T. Hastings J.W. Cellular control of the synthesis and activity of the bacterial luminescent system J. Bacteriol. 1970 104 313 322 5473898 10.1128/jb.104.1.313-322.1970 PMC248216
46. Eberhard A. Inhibition and activation of bacterial luciferase synthesis J. Bacteriol. 1972 109 1101 1105 5011244 10.1128/jb.109.3.1101-1105.1972 PMC247330
47. Grandclément C. Tannières M. Moréra S. Dessaux Y. Faure D. Quorum quenching: Role in nature and applied developments FEMS Microbiol. Rev. 2016 40 86 116 10.1093/femsre/fuv038 26432822
48. Gajdács M. Urbán E. Epidemiological Trends and Resistance Associated with Stenotrophomonas maltophilia Bacteremia: A 10-Year Retrospective Cohort Study in a Tertiary-Care Hospital in Hungary Diseases 2019 7 41 10.3390/diseases7020041 31159258 PMC6631814
49. Turovskiy Y. Kashtanov D. Paskhover B. Chikindas M.L. Quorum Sensing: Fact, Fiction, and Everything in Between Adv. Appl. Microbiol. 2007 62 191 234 17869606 10.1016/S0065-2164(07)62007-3 PMC2391307
50. Rutherford S.T. Bassler B.L. Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control Cold Spring Harb. Perspect. Med. 2012 2 a012427 10.1101/cshperspect.a012427 23125205 PMC3543102
51. Fleitas Martínez O. Cardoso M.H. Ribeiro S.M. Franco O.L. Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition Front. Cell Infect. Microbiol. 2019 9 74 10.3389/fcimb.2019.00074 31001485 PMC6454102
52. Bhardwaj A.K. Vinothkumar K. Rajpara N. Bacterial quorum sensing inhibitors: Attractive alternatives for control of infectious pathogens showing multiple drug resistance Recent Pat. Anti-Infect. Drug Discov. 2013 8 68 83 10.2174/1574891X11308010012 23394143
53. Pushpakom S. Iorio F. Eyers P.A. Escott K.J. Hopper S. Wells A. Doig A. Guilliams T. Latimer J. McNamee C. Drug repurposing: Progress, challenges and recommendations Nat. Rev. Drug Discov. 2019 18 41 58 10.1038/nrd.2018.168 30310233
54. Paul S.M. Mytelka D.S. Dunwiddie C.T. Persinger C.C. Munos B.H. Lindborg S.R. Schacht A.L. How to improve R&D productivity: The pharmaceutical industry’s grand challenge Nat. Rev. Drug Discov. 2010 9 203 214 20168317 10.1038/nrd3078
55. Miró-Canturri A. Ayerbe-Algaba R. Smani Y. Drug Repurposing for the Treatment of Bacterial and Fungal Infections Front. Microbiol. 2019 10 41 10.3389/fmicb.2019.00041 30745898 PMC6360151
56. Gatta V. Ilina P. Porter A. McElroy S. Tammela P. Targeting Quorum Sensing: High-Throughput Screening to Identify Novel LsrK Inhibitors Int. J. Mol. Sci. 2019 20 3112 10.3390/ijms20123112 31242708 PMC6627609
57. Yang L. Rybtke M.T. Jakobsen T.H. Hentzer M. Bjarnsholt T. Givskov M. Tolker-Nielsen T. Computer-Aided Identification of Recognized Drugs as Pseudomonas aeruginosa Quorum-Sensing Inhibitors AAC 2009 53 2432 2443 10.1128/AAC.01283-08 19364871 PMC2687250
58. Soo V.W.C. Kwan B.W. Quezada H. Castillo-Juárez I. Pérez-Eretza B. García-Contreras S.J. Martínez-Vázquez M. Wood T.K. García-Contreras R. Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections Available online: http://www.eurekaselect.com/145957/article (accessed on 27 October 2019) 10.2174/1568026616666160930131737 27697046
59. Varga B. Csonka Á. Csonka A. Molnár J. Amaral L. Spengler G. Possible Biological and Clinical Applications of Phenothiazines Anticancer Res. 2017 37 5983 5993 29061777 10.21873/anticanres.12045
60. Amaral L. Martins A. Spengler G. Molnar J. Efflux pumps of Gram-negative bacteria: What they do, how they do it, with what and how to deal with them Front. Pharm. 2014 4 168 10.3389/fphar.2013.00168 24427138 PMC3879458
61. Galm U. Hager M.H. Van Lanen S.G. Ju J. Thorson J.S. Shen B. Antitumor antibiotics: Bleomycin, enediynes, and mitomycin Chem. Rev. 2005 105 739 758 10.1021/cr030117g 15700963
62. Young C.W. Actinomycin and Antitumor Antibiotics Am. J. Clin. Pathol. 1969 52 130 137 10.1093/ajcp/52.2.130 5798361
63. Spengler G. Gajdács M. Marć M.A. Domínguez-Álvarez E. Sanmartín C. Organoselenium Compounds as Novel Adjuvants of Chemotherapy Drugs-A Promising Approach to Fight Cancer Drug Resistance Molecules 2019 24 336 10.3390/molecules24020336 30669343 PMC6359065
64. Ichikawa Y. Ghanefar M. Bayeva M. Wu R. Khechaduri A. Naga Prasad S.V. Mutharasan R.K. Naik T.J. Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation J. Clin. Invest. 2014 124 617 630 10.1172/JCI72931 24382354 PMC3904631
65. Ko H.H.T. Lareu R.R. Dix B.R. Hughes J.D. Statins: Antimicrobial resistance breakers or makers? PeerJ 2017 5 e3952 10.7717/peerj.3952 29085751 PMC5659212
66. Parihar S.P. Guler R. Khutlang R. Lang D.M. Hurdayal R. Mhlanga M.M. Suzuki H. Marais A.D. Brombacher F. Statin Therapy Reduces the Mycobacterium tuberculosis Burden in Human Macrophages and in Mice by Enhancing Autophagy and Phagosome Maturation J. Infect. Dis. 2014 209 754 763 10.1093/infdis/jit550 24133190
67. D’Angelo F. Baldelli V. Halliday N. Pantalone P. Polticelli F. Fiscarelli E. Williams P. Visca P. Leoni L. Rampioni G. Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa AAC 2018 62 e01296 e01318 10.1128/AAC.01296-18 30201815 PMC6201120
68. Ashraf S. Chaudhry U. Raza A. Ghosh D. Zhao X. In vitro activity of ivermectin against Staphylococcus aureus clinical isolates Antimicrob. Resist. Infect. Control. 2018 7 27 10.1186/s13756-018-0314-4 29468054 PMC5819080
69. Thangamani S. Younis W. Seleem M.N. Repurposing celecoxib as a topical antimicrobial agent Front. Microbiol. 2015 6 750 10.3389/fmicb.2015.00750 26284040 PMC4517059
70. Kincses A. Varga B. Csonka Á. Sancha S. Mulhovo S. Madureira A.M. Ferreira M.-J.U. Spengler G. Bioactive compounds from the African medicinal plant Cleistochlamys kirkii as resistance modifiers in bacteria Phytother. Res. 2018 32 1039 1046 10.1002/ptr.6042 29464798
71. Szabó M.A. Varga G.Z. Hohmann J. Schelz Z. Szegedi E. Amaral L. Molnár J. Inhibition of quorum-sensing signals by essential oils Phytother. Res. 2010 24 782 786 10.1002/ptr.3010 19827025
72. Imperi F. Leoni L. Visca P. Antivirulence activity of azithromycin in Pseudomonas aeruginosa Front. Microbiol. 2014 5 178 10.3389/fmicb.2014.00178 24795709 PMC4001013
73. Christensen L.D. van Gennip M. Jakobsen T.H. Alhede M. Hougen H.P. Høiby N. Bjarnsholt T. Givskov M. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model J. Antimicrob. Chemother. 2012 67 1198 1206 10.1093/jac/dks002 22302561
74. Henriksen K. Rørbo N. Rybtke M.L. Martinet M.G. Tolker-Nielsen T. Høiby N. Middelboe M. Ciofu O.P. Aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage–ciprofloxacin combination—Monitoring the phage–P. aeruginosa biofilms interactions Pathog. Dis. 2019 77 ftz011 10.1093/femspd/ftz011 30821815
75. Richter A.M. Fazli M. Schmid N. Shilling R. Suppiger A. Givskov M. Eberl L. Tolker-Nielsen T. Key Players and Individualists of Cyclic-di-GMP Signaling in Burkholderia cenocepacia Front. Microbiol. 2018 9 3286 10.3389/fmicb.2018.03286 30687272 PMC6335245
76. Bjarnsholt T. van Gennip M. Jakobsen T.H. Christensen L.D. Jensen P.Ø. Givskov M. In vitro screens for quorum sensing inhibitors and in vivo confirmation of their effect Nat. Protoc. 2010 5 282 293 10.1038/nprot.2009.205 20134428
77. Gajdács M. Resistance trends and epidemiology of Aeromonas and Plesiomonas infections (RETEPAPI): A 10-year retrospective survey Infect. Dis. 2019 51 710 713 10.1080/23744235.2019.1640389 31298069
78. Sciaky D. Montoya A.L. Chilton M.-D. Fingerprints of Agrobacterium Ti plasmids Plasmid 1978 1 238 253 10.1016/0147-619X(78)90042-2 748949
79. Lee J. Zhang L. The hierarchy quorum sensing network in Pseudomonas aeruginosa Protein Cell 2015 6 26 41 10.1007/s13238-014-0100-x 25249263 PMC4286720
80. Van Houdt R. Givskov M. Michiels C.W. Quorum sensing in Serratia FEMS Microbiol. Rev. 2007 31 407 424 10.1111/j.1574-6976.2007.00071.x 17459113
81. Surette M.G. Miller M.B. Bassler B.L. Quorum sensing in Escherichia coli, Salmonella typhimurium, and Vibrio harveyi: A new family of genes responsible for autoinducer production Proc. Natl. Acad. Sci. USA 1999 96 1639 1644 10.1073/pnas.96.4.1639 9990077 PMC15544
82. Gajdács M. The significance of bacterial quorum sensing (QS) inhibition in antivirulence therapy Diszciplínák Találkozása–Nyelvek és Kultúrák Érintkezése Határhelyzetek Hungarian Ministry of Foreign Affairs and Trade Budapest, Hungary 2019 Volume XI 396 406 978-615-5389-72-6
83. Gajdács M. Burián K. Terhes G. Resistance Levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of Inpatients and Outpatients (RENFUTI): A 10-Year Epidemiological Snapshot Antibiotics 2019 8 143 10.3390/antibiotics8030143 PMC6784256 31505817
84. Al-Bakri A.G. Othman G. Bustanji Y. The assessment of the antibacterial and antifungal activities of aspirin, EDTA and aspirin-EDTA combination and their effectiveness as antibiofilm agents J. Appl. Microbiol. 2009 107 280 286 10.1111/j.1365-2672.2009.04205.x 19302313
85. Givskov M. Beyond nutrition: Health-promoting foods by quorum-sensing inhibition Future Microbiol. 2012 7 1025 1028 10.2217/fmb.12.84 22953702
86. Ding T. Li T. Wang Z. Li J. Curcumin liposomes interfere with quorum sensing system of Aeromonas sobria and in silico analysis Sci. Rep. 2017 7 1 16 10.1038/s41598-017-08986-9 28819178 PMC5561023
87. Thangamani S. Mohammad H. Abushahba M.F.N. Sobreira T.J.P. Hedrick V.E. Paul L.N. Seleem M.N. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens Sci. Rep. 2016 6 1 13 10.1038/srep22571 26936660 PMC4776257
88. Jakobsen T.H. Bragason S.K. Phipps R.K. Christensen L.D. van Gennip M. Alhede M. Skindersoe M. Larsen T.O. Høiby N. Bjarnsholt T. Food as a source for quorum sensing inhibitors: Iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa Appl. Environ. Microbiol. 2012 78 2410 2421 10.1128/AEM.05992-11 22286987 PMC3302586
89. Antoniani D. Rossi E. Rinaldo S. Bocci P. Lolicato M. Paiardini A. Raffaelli N. Cutruzzolà F. Landini P. The immunosuppressive drug azathioprine inhibits biosynthesis of the bacterial signal molecule cyclic-di-GMP by interfering with intracellular nucleotide pool availability Appl. Microbiol. Biotechnol. 2013 97 7325 7336 10.1007/s00253-013-4875-0 23584245
90. Paczkowski J.E. Mukherjee S. McCready A.R. Cong J.-P. Aquino C.J. Kim H. Henke B.R. Smith C.D. Bassler B.L. Flavonoids Suppress Pseudomonas aeruginosa Virulence through Allosteric Inhibition of Quorum-sensing Receptors J. Biol. Chem. 2017 292 4064 4076 10.1074/jbc.M116.770552 28119451 PMC5354481
91. Kim W. Zou G. Hari T.P.A. Wilt I.K. Zhu W. Galle N. Faizi H.A. Hendricks G.L. Tori K. Pan W. A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus Proc. Natl. Acad. Sci. USA 2019 116 16529 16534 10.1073/pnas.1904700116 31358625 PMC6697817
92. Gökalsın B. Aksoydan B. Erman B. Sesal N.C. Reducing Virulence and Biofilm of Pseudomonas aeruginosa by Potential Quorum Sensing Inhibitor Carotenoid: Zeaxanthin Microb. Ecol. 2017 74 466 473 10.1007/s00248-017-0949-3 28255686
93. Bansal T. Englert D. Lee J. Hegde M. Wood T.K. Jayaraman A. Differential Effects of Epinephrine, Norepinephrine, and Indole on Escherichia coli O157:H7 Chemotaxis, Colonization, and Gene Expression Infect. Immun. 2007 75 4597 4607 10.1128/IAI.00630-07 17591798 PMC1951185
94. Sun J. Marais J.P.J. Khoo C. LaPlante K. Vejborg R.M. Givskov M. Tolker-Nielsen T. Seeram N.P. Rowley D.C. Cranberry (Vaccinium macrocarpon) oligosaccharides decrease biofilm formation by uropathogenic Escherichia coli J. Funct. Foods 2015 17 235 242 10.1016/j.jff.2015.05.016 26613004 PMC4657873
95. Duan J. Li M. Hao Z. Shen X. Liu L. Jin Y. Wang S. Guo Y. Yang L. Wang L. Subinhibitory concentrations of resveratrol reduce alpha-hemolysin production in Staphylococcus aureus isolates by downregulating saeRS Emerg. Microbes Infect. 2018 7 1 10 10.1038/s41426-018-0142-x 30065273 PMC6068196
96. Zhang Y. Sass A. Van Acker H. Wille J. Verhasselt B. Van Nieuwerburgh F. Kaever V. Crabbé A. Coenye T. Coumarin Reduces Virulence and Biofilm Formation in Pseudomonas aeruginosa by Affecting Quorum Sensing, Type III Secretion and C-di-GMP Levels Front. Microbiol. 2018 9 1952 10.3389/fmicb.2018.01952 30186266 PMC6110822
97. Rajkumari J. Borkotoky S. Murali A. Suchiang K. Mohanty S.K. Busi S. Attenuation of quorum sensing controlled virulence factors and biofilm formation in Pseudomonas aeruginosa by pentacyclic triterpenes, betulin and betulinic acid Microb. Pathog. 2018 118 48 60 10.1016/j.micpath.2018.03.012 29526565
98. Jakobsen T.H. van Gennip M. Phipps R.K. Shanmugham M.S. Christensen L.D. Alhede M. Skindersoe M.E. Rasmussen T.B. Friedrich K. Uthe F. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing Antimicrob. Agents Chemother. 2012 56 2314 2325 10.1128/AAC.05919-11 22314537 PMC3346669
99. Routh M.M. Chauhan N.M. Karuppayil S.M. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans Braz. J. Microbiol. 2013 44 855 859 10.1590/S1517-83822013000300029 24516452 PMC3910200
100. Poli J.-P. Guinoiseau E. de Rocca Serra D. Sutour S. Paoli M. Tomi F. Quilichini Y. Berti L. Lorenzi V. Anti-Quorum Sensing Activity of 12 Essential Oils on chromobacterium violaceum and Specific Action of cis-cis-p-Menthenolide from Corsican Mentha suaveolens ssp. Insularis Molecules 2018 23 2125 10.3390/molecules23092125 30142938 PMC6225197
101. Hendrix A.S. Spoonmore T.J. Wilde A.D. Putnam N.E. Hammer N.D. Snyder D.J. Guelcher S.A. Skaar E.P. Cassat J.E. Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus Osteomyelitis Antimicrob. Agents Chemother. 2016 60 5322 5330 10.1128/AAC.00834-16 27324764 PMC4997817
102. Chavez-Dozal A.A. Lown L. Jahng M. Walraven C.J. Lee S.A. In Vitro Analysis of Finasteride Activity against Candida albicans Urinary Biofilm Formation and Filamentation AAC 2014 58 5855 5862 10.1128/AAC.03137-14 PMC4187923 25049253
103. Yeo W.-S. Arya R. Kim K.K. Jeong H. Cho K.H. Bae T. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus Sci. Rep. 2018 8 1 10 10.1038/s41598-018-20617-5 29410445 PMC5802796
104. Abbas H.A. Shaldam M.A. Glyceryl trinitrate is a novel inhibitor of quorum sensing in Pseudomonas aeruginosa Afr. Health Sci. 2016 16 1109 1117 10.4314/ahs.v16i4.29 28479904 PMC5398458
105. Ogundeji A.O. Pohl C.H. Sebolai O.M. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs Antimicrob. Agents Chemother. 2016 60 4799 4808 10.1128/AAC.02810-15 27246782 PMC4958236
106. Gocmen S. Buyukkocak U. Caglayan O. In vitro investigation of the antibacterial effect of ketamine Ups. J. Med. Sci. 2008 113 39 46 10.3109/2000-1967-211 18521797
107. Johnson S.M. Saint John B.E. Dine A.P. Local Anesthetics as Antimicrobial Agents: A Review Surg. Infect. 2008 9 205 213 10.1089/sur.2007.036 18426354
108. Abbas H.A. Elsherbini A.M. Shaldam M.A. Repurposing metformin as a quorum sensing inhibitor in Pseudomonas aeruginosa Afr. Health Sci. 2017 17 808 819 10.4314/ahs.v17i3.24 29085409 PMC5656202
109. Koch G. Wermser C. Acosta I.C. Kricks L. Stengel S.T. Yepes A. Lopez D. Attenuating Staphylococcus aureus Virulence by Targeting Flotillin Protein Scaffold Activity Cell Chem. Biol. 2017 24 845 857.e6 10.1016/j.chembiol.2017.05.027 28669526 PMC5536197
110. Imperi F. Massai F. Pillai C.R. Longo F. Zennaro E. Rampioni G. Visca P. Leoni L. New Life for an Old Drug: The Anthelmintic Drug Niclosamide Inhibits Pseudomonas aeruginosa Quorum Sensing Antimicrob. Agents Chemother. 2013 57 996 1005 10.1128/AAC.01952-12 23254430 PMC3553739
111. Kalia M. Yadav V.K. Singh P.K. Sharma D. Narvi S.S. Agarwal V. Exploring the impact of parthenolide as anti-quorum sensing and anti-biofilm agent against Pseudomonas aeruginosa Life Sci. 2018 199 96 103 10.1016/j.lfs.2018.03.013 29524516
112. Gerits E. Defraine V. Vandamme K. Cremer K.D. Brucker K.D. Thevissen K. Cammue B.P.A. Beullens S. Fauvart M. Verstraeten N. Repurposing Toremifene for Treatment of Oral Bacterial Infections Antimicrob. Agents Chemother. 2017 61 e01846 e01916 10.1128/AAC.01846-16 27993858 PMC5328575
113. Tintino S.R. Morais-Tintino C.D. Campina F.F. Pereira R.L. Costa M.d.S. Braga M.F.B.M. Limaverde P.W. Andrade J.C. Siqueira-Junior J.P. Coutinho H.D.M. Action of cholecalciferol and alpha-tocopherol on Staphylococcus aureus efflux pumps EXCLI J. 2016 15 315 322 27298617 10.17179/excli2016-277 PMC4897629
114. Kwiecińska-Piróg J. Skowron K. Bogiel T. Białucha A. Przekwas J. Gospodarek-Komkowska E. Vitamin C in the Presence of Sub-Inhibitory Concentration of Aminoglycosides and Fluoroquinolones Alters Proteus mirabilis Biofilm Inhibitory Rate Antibiotics 2019 8 116 10.3390/antibiotics8030116 PMC6783857 31405233
115. Andrade J.C. Braga M.F.B.M. Guedes G.M.M. Tintino S.R. Freitas M.A. Quintans L.J. Jr. Menezes I.R.A. Coutinho H.D.M. Cholecalciferol, Ergosterol, and Cholesterol Enhance the Antibiotic Activity of Drugs Int. J. Vitam. Nutr. Res. 2018 88 244 250 10.1024/0300-9831/a000268 31124408
116. Andrade J.C. Morais Braga M.F.B. Guedes G.M.M. Tintino S.R. Freitas M.A. Quintans L.J. Menezes I.R.A. Coutinho H.D.M. Menadione (vitamin K) enhances the antibiotic activity of drugs by cell membrane permeabilization mechanism Saudi J. Biol. Sci. 2017 24 59 64 10.1016/j.sjbs.2015.09.004 28053572 PMC5198922
117. Andrade J.C. Morais-Braga M.F.B. Guedes G.M.M. Tintino S.R. Freitas M.A. Menezes I.R.A. Coutinho H.D.M. Enhancement of the antibiotic activity of aminoglycosides by alpha-tocopherol and other cholesterol derivates Biomed. Pharmacother. 2014 68 1065 1069 10.1016/j.biopha.2014.10.011 25458794
118. Hojo M. Asahara T. Nagahara A. Takeda T. Matsumoto K. Ueyama H. Matsumoto K. Asaoka D. Takahaski T. Nomoto K. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors Dig. Dis Sci. 2018 63 2940 2949 10.1007/s10620-018-5122-4 29796911 PMC6182435
119. Cha C. Gao P. Chen Y.C. Shaw P.D. Farrand S.K. Production of acyl-homoserine lactone quorum-sensing signals by gram-negative plant-associated bacteria Mol. Plant. Microbe Interact. 1998 11 1119 1129 10.1094/MPMI.1998.11.11.1119 9805399
120. Morohoshi T. Shiono T. Takidouchi K. Kato M. Kato N. Kato J. Ikeda T. Inhibition of Quorum Sensing in Serratia marcescens AS-1 by Synthetic Analogs of N-Acylhomoserine Lactone Appl. Env. Microbiol. 2007 73 6339 6344 10.1128/AEM.00593-07 17675425 PMC2075062
121. Nacsa-Farkas E. Kerekes E.B. Hargitai F. Vágvölgyi C. Szegedi E. Culture media supplemented with inorganic salts improve the growth and viability of several bacterial strains Acta Biol. Szeged. 2016 60 151 156